Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment

Core Insights - Novo Nordisk's GLP-1 drug semaglutide showed no cognitive benefit for individuals with early Alzheimer's disease according to findings from two large trials [1] Group 1 - The trials were presented at a medical meeting, indicating a significant event in the medical research community [1] - The results have dashed hopes that semaglutide, a widely used medication, could assist patients with early Alzheimer's disease [1]